Want to see AU:IXC full AI Analyst Report?
Total Valuation
Invex Therapeutics Ltd. has a market cap or net worth of AU$7.89M. The enterprise value is AU$2.75M.
Market CapAU$7.89M
Enterprise ValueAU$2.75M
Share Statistics
Invex Therapeutics Ltd. has 75,153,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,153,850
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Invex Therapeutics Ltd.’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-38.18%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-338.09K
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Invex Therapeutics Ltd. is ―. Invex Therapeutics Ltd.’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.00
PB Ratio1.73
Price to FCF-4.98
Price to Operating Cash Flow-6.08
PEG Ratio-0.03
Income Statement
In the last 12 months, Invex Therapeutics Ltd. had revenue of 0.00 and earned -1.35M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit0.00
Operating Income-1.54M
Pretax Income-1.40M
Net Income-1.35M
EBITDA-1.54M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -1.36M and capital expenditures 0.00, giving a free cash flow of -1.36M billion.
Operating Cash Flow-1.36M
Free Cash Flow-1.36M
Free Cash Flow per Share-0.02
Dividends & Yields
Invex Therapeutics Ltd. pays an annual dividend of AU$0.186, resulting in a dividend yield of 248.4%
Dividend Per ShareAU$0.186
Dividend Yield248.4%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change-17.86%
50-Day Moving Average0.11
200-Day Moving Average0.11
Relative Strength Index (RSI)30.64
Average Volume (3m)10.23K
Important Dates
Invex Therapeutics Ltd. upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateFeb 18, 2027
Ex-Dividend Date―
Financial Position
Invex Therapeutics Ltd. as a current ratio of 26.48, with Debt / Equity ratio of 0.00%
Current Ratio26.48
Quick Ratio26.48
Debt to Market Cap0.00
Net Debt to EBITDA0.98
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Invex Therapeutics Ltd. has paid -46.83K in taxes.
Income Tax-46.83K
Effective Tax Rate0.03
Enterprise Valuation
Invex Therapeutics Ltd. EV to EBITDA ratio is -3.40, with an EV/FCF ratio of -3.86.
EV to Sales0.00
EV to EBITDA-3.40
EV to Free Cash Flow-3.86
EV to Operating Cash Flow-3.86
Balance Sheet
Invex Therapeutics Ltd. has AU$4.02M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$4.02M billion.
Cash & Marketable SecuritiesAU$4.02M
Total DebtAU$0.00
Net CashAU$4.02M
Net Cash Per ShareAU$0.05
Tangible Book Value Per ShareAU$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Invex Therapeutics Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-185.71%